LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Listă Acțiuni・Incyte Corp

Incyte Corp

Deschisă

SectorSănătate

99.05 -1.26

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

98.35

Maxim

101.08

Indicatori cheie
By Trading Economics
Venit	4.1M 303M
Vânzări	-234M 1.3B
P/E Medie Sector	13.682 49.8
EPS	1.81
Marjă de profit	23.834
Angajați	2,844
EBITDA	-47M 367M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+8.78% upside

Dividende
By Dow Jones
Următoarele câștiguri	28 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	358M 19B
Deschiderea anterioară	100.31
Închiderea anterioară	99.05

Sentimentul știrilor

By Acuity

23%

77%

70 / 346 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

59.52 / 62.66 Suport & Rezistență

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 mai 2026, 22:15 UTC

Achiziții, Fuziuni, Preluări

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mai 2026, 22:32 UTC

Câștiguri

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mai 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mai 2026, 21:49 UTC

Câștiguri

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mai 2026, 21:32 UTC

Achiziții, Fuziuni, Preluări

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mai 2026, 21:32 UTC

Achiziții, Fuziuni, Preluări

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mai 2026, 21:32 UTC

Achiziții, Fuziuni, Preluări

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mai 2026, 21:32 UTC

Achiziții, Fuziuni, Preluări

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mai 2026, 21:31 UTC

Achiziții, Fuziuni, Preluări

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mai 2026, 21:23 UTC

Achiziții, Fuziuni, Preluări

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mai 2026, 21:12 UTC

Câștiguri

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mai 2026, 21:12 UTC

Câștiguri

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 mai 2026, 20:44 UTC

Câștiguri

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mai 2026, 20:43 UTC

Câștiguri

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mai 2026, 20:32 UTC

Câștiguri

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mai 2026, 20:32 UTC

Câștiguri

CleanSpark 2Q Rev $136.4M >CLSK

11 mai 2026, 20:30 UTC

Câștiguri

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mai 2026, 20:30 UTC

Câștiguri

Steris 4Q Cont Ops EPS $2.24 >STE

11 mai 2026, 20:30 UTC

Câștiguri

Steris 4Q Rev $1.6B >STE

11 mai 2026, 20:30 UTC

Câștiguri

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mai 2026, 20:30 UTC

Câștiguri

Steris 4Q Adj EPS $2.83 >STE

11 mai 2026, 20:22 UTC

Acțiuni populare

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mai 2026, 19:37 UTC

Câștiguri

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

8.78% sus

Prognoză pe 12 luni

Medie 109.13 USD 8.78%

Maxim 135 USD

Minim 75 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 17 analiști care au acordat evaluări ale acțiunilor Incyte Corp - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

59.52 / 62.66Suport & Rezistență

Bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

70 / 346 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation